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Problem statement
In Belgium, the average annual growth rate of per capita
health spending decreased from 2.3% between 2000 and
2006 to 1.6% between 2007 and 2013 [1]. Nonetheless,
Belgium’s Gross Domestic Product (GDP) grew at mark-
edly lower rates (2.1% and 0.8%, respectively), implying
that pressures on sustaining affordable and equitable
health care increase.
Objectives
We assessed the impact of co-payment regulations on
prices and sales figures for atorvastatin in Belgium
before and after the patent expiry in 2013.
Policies targeted: Reference pricing system; Copayment
regulations.
Region covered: EURO: Belgium (national)
Methods
We related sales figures to coinciding price evolutions, and
broke the costs down by their bearer. On the one hand we
analysed a data extraction from IMS Health for Belgium
for the period 2007-2013. The IMS Health database con-
tains sales figures of a representative sample of community
pharmacies including the number of packages sold (per
CNK number) per month. On the other hand, we studied
the corresponding unit price tables of the Belgian centre
for Pharmaco-therapeutic Information (BCFI, an indepen-
dent source).
Results
In March 2013, the public price for Lipitor® 98*80 mg
was EUR 123.51, and the price for Atorvastatin Mylan®
(same package size) was EUR 62.52. The co-payment
amount borne by patients was the same for these pro-
ducts (EUR 14.5 for each), but the costs borne by the
government through the National Institute for Health
and Disability Insurance (NIHDI) were markedly different
(i.e. EUR 109.1 for Lipitor and EUR 48.02 for the generic
Atorvastatin). For the 19,777 reimbursed packages of
brand atorvastatin in 2013, the latter (reimbursed) costs
amounted to EUR 2,157,671, which is about 1 million
EURO more than would have been required to cover the
same sales volume of the equivalent generic. Both
packages were considered low-cost medicines resulting in
the same ‘minimized’ patient’s contribution, thereby elim-
inating any incentive for the physician or patient to
choose a generic medicine.
Conclusions
In this case, the reference pricing system was a vain
attempt to curb public drug expenditures. Looking
ahead at the patent expiry of rosuvastatin in 2016, the
effectiveness of existing regulations to curb growing
pharmaceutical expenditures requires urgent reconsi-
deration, based on the lessons learnt from case studies
such as ours. A potentially feasible option would be to
abolish the maximum co-payment level per package in
the Belgian reimbursement system for therapeutically
interchangeable drugs.
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